Futibatinib has clear contraindications for patients with severe liver and kidney dysfunction and eye lesions, and strict risk assessment is required. The following provides a detailed explanation of the classification of taboo populations and key clinical management points.

1. Patients with severe liver dysfunction

Fubatinib is contraindicated for patients with Child Pugh grade C liver dysfunction. Patients with mild to moderate liver function impairment should reduce their dosage and closely monitor ALT/AST levels. It is recommended to lower the initial dose to 80mg/day.

2. Patients with severe renal insufficiency

Patients with severe renal impairment and eGFR<30mL/min are contraindicated. Patients with mild to moderate renal insufficiency do not need to adjust the dosage, but need to increase the frequency of creatinine monitoring. It is recommended to evaluate changes in renal function every week.

3. Patients with active eye lesions

Patients with active eye diseases such as retinal pigment epithelium detachment are prohibited from using it. Before medication, a baseline fundus examination must be completed, and a follow-up examination should be conducted every 8 weeks during the treatment period. If any visual abnormalities occur, the medication should be stopped immediately and an ophthalmic consultation should be held.

4. Additional explanation for special groups

Prohibited during pregnancy (may cause fetal malformation), feeding should be suspended during lactation. Elderly patients do not need to adjust the dosage but need to strengthen monitoring. The safety of medication for children has not yet been established.